Feasibility Study of SmartMatch Analysis Using Standard Surgery or Biopsy to Guide Treatment in Rare Advanced Female Gynecologic Cancers

What this Trial Is About

Researchers are evaluating how easy it is to use tissue samples from standard surgical resections or biopsies for SmartMatch analysis to guide treatment options in advanced gynecological cancers. The study is observational and focuses on rare and advanced female gynecologic malignancies, including metastatic or unresectable tumors. It aims to determine if SmartMatch can generate actionable treatment recommendations within 28 days of tissue collection. Participants provide fresh tumor tissue obtained during standard of care surgery or biopsy, which is analyzed in the SmartMatch laboratory. Their medical records are also reviewed during the study. The study does not assign specific treatments but observes the use of SmartMatch analysis to inform treatment decisions by the Precision Medicine Tumor Board PMTB. During the study, participants will have tissue samples collected and their medical data reviewed. Researchers will track how often SmartMatch provides actionable treatment advice, the time needed to generate reports, and the implementation of PMTB-recommended therapies. Outcomes such as progression-free survival and growth modulation index will be measured over up to 36 months. Participants safety and ability to receive systemic therapy will also be monitored.

Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers